Milestone Pharmaceuticals Inc. (MIST)
NASDAQ: MIST · Real-Time Price · USD
0.9196
+0.0304 (3.42%)
At close: Sep 17, 2026, 4:00 PM EDT
0.9200
+0.0004 (0.04%)
After-hours: Sep 17, 2026, 4:41 PM EDT
Milestone Pharmaceuticals Revenue
Milestone Pharmaceuticals had revenue of $559.00K in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $2.34M. In the year 2025, Milestone Pharmaceuticals had annual revenue of $1.55M.
Revenue (ttm)
$2.34M
Revenue Growth
n/a
P/S Ratio
54.16
Revenue / Employee
$61,658
Employees
38
Market Cap
129.58M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.55M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 1.00M | -4.00M | -80.00% |
| Dec 31, 2022 | 5.00M | -10.00M | -66.67% |
| Dec 31, 2021 | 15.00M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Cellectis | 63.82M |
| LENZ Therapeutics | 21.48M |
| Caribou Biosciences | 10.04M |
| Equillium | 4.39M |
| Inovio Pharmaceuticals | 65.34K |
MIST News
- 2 days ago - Milestone Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 9 days ago - Milestone Pharmaceuticals Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 14 days ago - Milestone Pharmaceuticals announces NMPA approval of etripamil for PSVT - TheFly
- 14 days ago - Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States - GlobeNewsWire
- 15 days ago - Milestone Pharmaceuticals to Present at Upcoming Investor Conferences - GlobeNewsWire
- 21 days ago - Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients' Daily Lives and Quality of Life Between Episodes - GlobeNewsWire
- 27 days ago - Milestone Pharmaceuticals enrolls first patient in ReVeRA-301 pivotal trial - TheFly
- 27 days ago - Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR) - GlobeNewsWire